These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 15084367)

  • 21. ["Persistent" angina: rationale for a metabolic approach].
    Marzilli M
    Ital Heart J; 2004 Mar; 5 Suppl 2():37S-41S. PubMed ID: 15074776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic approach to myocardial ischemia: a novel therapeutic strategy for patients with coronary artery disease?
    Rizzon P; Iliceto S; Marangelli V
    Cardiologia; 1995 Oct; 40(10):717-20. PubMed ID: 8819732
    [No Abstract]   [Full Text] [Related]  

  • 23. Ranolazine: new approach for the treatment of stable angina pectoris.
    Stanley WC
    Expert Rev Cardiovasc Ther; 2005 Sep; 3(5):821-9. PubMed ID: 16181027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
    MacInnes A; Fairman DA; Binding P; Rhodes Ja; Wyatt MJ; Phelan A; Haddock PS; Karran EH
    Circ Res; 2003 Aug; 93(3):e26-32. PubMed ID: 12869391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic modulators for chronic cardiac ischemia.
    Parang P; Singh B; Arora R
    J Cardiovasc Pharmacol Ther; 2005 Dec; 10(4):217-23. PubMed ID: 16382258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ranolazine: new paradigm for management of myocardial ischemia, myocardial dysfunction, and arrhythmias.
    Stone PH
    Cardiol Clin; 2008 Nov; 26(4):603-14. PubMed ID: 18929234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.
    Chaitman BR; Skettino SL; Parker JO; Hanley P; Meluzin J; Kuch J; Pepine CJ; Wang W; Nelson JJ; Hebert DA; Wolff AA;
    J Am Coll Cardiol; 2004 Apr; 43(8):1375-82. PubMed ID: 15093870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolic antianginal agent ranolazine offers good symptom relief in a patient with inoperable severe aortic stenosis.
    Athauda-Arachchi P; Lang C
    Cardiovasc Ther; 2012 Aug; 30(4):e210-1. PubMed ID: 21884008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Therapeutic application of myocardial cytoprotection].
    Ribeiro C
    Rev Port Cardiol; 1994 Sep; 13(9):669-70. PubMed ID: 7818940
    [No Abstract]   [Full Text] [Related]  

  • 30. Cardioprotective effects of trimetazidine: a review.
    Marzilli M
    Curr Med Res Opin; 2003; 19(7):661-72. PubMed ID: 14606990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Ranolazine--new treatment of chronic stable angina pectoris].
    Ahlehoff O; Hansen PR
    Ugeskr Laeger; 2009 Dec; 171(50):3705-7. PubMed ID: 20003868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucose, insulin and myocardial ischaemia.
    Devos P; Chioléro R; Van den Berghe G; Preiser JC
    Curr Opin Clin Nutr Metab Care; 2006 Mar; 9(2):131-9. PubMed ID: 16477178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ranolazine and other antianginal therapies in the era of the drug-eluting stent.
    Berger P
    JAMA; 2004 Jan; 291(3):365-7. PubMed ID: 14734600
    [No Abstract]   [Full Text] [Related]  

  • 34. [Ranolazine--an additional anti-anginal drug].
    Michels G; Kochanek M; Hoppe UC
    Dtsch Med Wochenschr; 2010 Oct; 135(41):2037-40. PubMed ID: 20925013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic stable angina pectoris.
    Jawad E; Arora R
    Dis Mon; 2008 Sep; 54(9):671-89. PubMed ID: 18725007
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical benefits of a metabolic approach with trimetazidine in revascularized patients with angina.
    Danchin N
    Am J Cardiol; 2006 Sep; 98(5A):8J-13J. PubMed ID: 16931200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Mechanisms of myocardial cell protection from ischemia/reperfusion injury and potential clinical implications].
    Lamendola P; Di Monaco A; Barone L; Pisanello C; Lanza GA; Crea F
    G Ital Cardiol (Rome); 2009 Jan; 10(1):28-36. PubMed ID: 19292017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ranolazine (Ranexa) in the treatment of chronic stable angina.
    Aslam S; Gray D
    Adv Ther; 2010 Apr; 27(4):193-201. PubMed ID: 20449698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of a novel anti-ischemic agent in acute coronary syndromes: design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial.
    Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Skene A; McCabe CH; Braunwald E;
    Am Heart J; 2006 Jun; 151(6):1186.e1-9. PubMed ID: 16781216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine.
    Stanley WC; Marzilli M
    Fundam Clin Pharmacol; 2003 Apr; 17(2):133-45. PubMed ID: 12667223
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.